Une veille sur la santé numérique en France et à l’international : politiques publiques, données, infrastructures, IA, services et usages. Études, rapports et retours de terrain sélectionnés par Lionel Reichardt, Pharmageek, pour comprendre les transformations et éclairer les décisions.
 Your new post is loading...
Your new post is loading...
Scoop.it!
No comment yet.
Sign up to comment
Scoop.it!
Web-based social network for women that have or have had breast cancer has been launched by Myhealthteam. Read about this company that is also behind a social networking site for parents of autistic children.
Via uri goren
Scoop.it!
Un nouveau portail dédié aux remplacements des professionnels de santé a fait son apparition sur la toile : Medcito.fr. Présentation.
Via Henri Lefèvre
Scoop.it!
Les sites eCommerce ont le vent en poupe. Voici une infographie qui présente le classement des plateformes e-Commerce les plus utilisées. Via Arobasenet
Scoop.it!
The next generation of doctors' surgeries could feature:
* Patient check in – already an effective solution providing the ability to self-check in for appointments
Scoop.it!
La SEP bouge : un site dédié à la Sclérose en plaques : diagnostic et conseils, témoignages patients, droits et démarches (Top story: Sclérose en plaques : la SEP-bouge.fr, un site dédié à la maladie
Scoop.it!
Play a sedentary video game and live a healthier life? That’s the hope of Yale researchers who are joining the booming health games industry with an iPad application designed to help minority teens learn about HIV prevention strategies. Via Giuseppe Fattori
Scoop.it!
While mHealth has the potential to overcome traditional obstacles to the delivery of health services to the poor in lower and middle-income countries--issues related to access, quality, time, and resources--there is little evidence as to whether the expected benefits and savings can be actualized on a large scale. As a first step to developing the investment case for mHealth, this article outlines some of the key economic and financial questions that need to be answered in developing in-country eHealth investments. The proposed questions focus on the costs of eHealth infrastructure; regulatory structures that provide incentives at different levels of the health delivery system to encourage investment in, and use of, eHealth; and measuring the outcomes of successful eHealth utilization, including anticipated return on investment. Via dbtmobile
Scoop.it!
From simple charts to complex maps and infographics, Brian Suda's round-up of the best – and mostly free – tools has everything you need to bring your data to life One of the most common questions I get asked is how to get started with data visualisations. Beyond following blogs, you need to practise – and to practise, you need to understand the tools available. In this article, I want to introduce you to 20 different tools for creating visualisations: from simple charts to complex graphs, maps and infographics. Almost everything here is available for free, and some you have probably installed already. Via Frédéric DEBAILLEUL
Scoop.it!
statistiques en temps réel sur les requêtes sur GOOGLE.
Scoop.it!
Internet has become the defining medium of the last two decades. But what we know about its impact in the field of medicine is other thing. How beneficial or detrimental could it be?
Via uri goren
|
Scoop.it!
Big Pharma's image problem, fueled by numerous high-profile scandals, may have made doctors so skeptical of the industry that it's warping their judgment, a new survey suggests. Researchers found that doctors shown summaries of hypothetical drug tests lost their confidence in the results when a pharmaceutical company had paid for the studies. Doctors were less willing to prescribe the drug under study, and they even downgraded the very scientific methods they would praise when drugmakers hadn't backed the research. "I think skepticism is appropriate, but at some point the methods of the research should provide reassurance," said Dr. Aaron Kesselheim of the Harvard Medical School in Boston, who led the work. Several studies have shown reports in medical journals often cast drugs in a flattering light when the sponsor has money riding on the results. There are also concerns that companies may rig clinical trials in subtle ways to boost the chances that their drug will shine, or spin or hide unfavorable data. That was the case for GlaxoSmithKline's diabetes pill Avandia. As part of the British drugmaker's $3 billion healthcare fraud settlement earlier this year, the company conceded it had failed to provide safety data to the U.S. Food and Drug Administration and had made unsubstantiated safety claims. Another controversial drug, Merck & Co's painkiller Vioxx, was recalled in 2004 after it became clear that it had dangerous side effects. Four years prior, researchers backed by Merck had seen a five-fold jump in heart attacks in patients taking Vioxx compared with naproxen, an established painkiller. But they had framed it as a five-fold decrease in heart attacks with the older drug. One of the ways scientific journals have tried to address this perceived bias is by making sure any potential conflict of interest, such as financial ties to drug companies, are disclosed in research reports. But it isn't totally clear what effect that has on readers, Kesselheim said. LITTLE CREDIBILITY His team came up with a set of imaginary FDA-approved drugs - lampytinib, bondaglutaraz and provasinab - and then created "abstracts" describing clinical trials of each of the drugs as if for a scientific report. The researchers also varied the funding source and the quality of the research methods, ending up with 27 different abstracts of hypothetical drug tests. Overall, the 269 doctors surveyed were able to separate the low-quality trials from the better ones. They also had less confidence in drugs studied in low-quality trials and were more reluctant to prescribe them. Regardless of research quality, however, doctors tended to distrust trials with support from pharmaceutical companies as opposed to no funding or funding from the National Institutes of Health. For example, they were only half as willing to prescribe a drug when the trial had been sponsored by the industry than when the government had paid for it. "There was this lack of credibility of industry-funded trials," Kesselheim told Reuters Health, adding that the skepticism could make it harder for new effective medications to gain a foothold. Matthew Bennett of Pharmaceutical Research and Manufacturers of America, a trade group, said collaboration between industry and academia is critical for the discovery of new drugs. "Unfortunately, when taken out of context, publicly available information about physician interactions with biopharmaceutical companies does not convey the value of these relationships, which advance science and promote high-quality patient care," he said in an emailed statement to Reuters Health. TRUST OR NOT In an editorial published along with the survey in the New England Journal of Medicine, editor-in-chief Dr. Jeffrey Drazen said the journal has taken steps to improve the reporting of clinical trials. Those steps include requiring that the study is registered in a public database from the outset, publishing study protocols for clinical trials and posting any conflict of interest authors might have, according to the editorial, entitled "Believe the Data." Those measures aren't enough to satisfy all experts, however. "We are doing the best we can, but there is still good reason to be skeptical," said Brett Thombs of McGill University in Montreal, Canada, who has studied disclosure in medical journals. "The idea that we can cast aside all doubts and skepticism is naïve." Thombs said there are several important variables in a clinical trial that can influence its results, such as how faithfully trial participants take their drugs and how the outcomes are assessed, and not all are easy to identify. "There are numerous factors that are more nuanced than you can get from a few variables," he told Reuters Health. "I don't think we want to throw out a study just because it's funded by a pharmaceutical company, but we are always skeptical. Via Richard Meyer
Scoop.it!
Here is a sneak peek at exclusive CMI research on areas where the health care industry needs to step up its content marketing game.
Via Dean Berg
Scoop.it!
See who we awarded with our...
"After reviewing hundreds of websites, Pacific Medical Training is happy to award these sites with our "Best of Doctor Sites" Award. We fully appreciate and can understand the time and commitment it takes to maintain a website and continue to provide current content easily accessible to the sites viewers. Websites
Via Camilo Erazo
Scoop.it!
Scoop.it!
Experts from across the world are gathering in Moray for a conference looking at the benefits of digital healthcare.
New technology, which allows patients to report their symptoms using computers in their home, is being seen as a major boost for people living in remote areas as it allows doctors to monitor them more closely.
A pilot scheme run by NHS Grampian allows respiratory patients, for example, to use a touchscreen computer to report to their doctor's surgery and check their own breathing and oxygen levels using specialist kit.
More than a hundred delegates from across the world have gathered in Forres to discuss the digital health technology, which is can also be useful in remote regions where it can be difficult to reach a doctor. Experts say digital healthcare can also cut costs and give patients greater control over their well-being.
It is hoped the conference will also forge links between countries hoping to implement the technology. Via dbtmobile
Scoop.it!
Natural language processing (NLP) applications could become a powerful aid to clinical researchers, according to a study published July 21 in the Journal of the American Medical Informatics Association.
Via uri goren
Scoop.it!
Innovation en santé : les nouvelles voies de la rechercheLes ÉchosAlors que le secteur de la santé est présenté comme un champ d'opportunités - le vieillissement de la population entraîne des besoins de soins nouveaux et importants, les pays...
Scoop.it!
It’s something of an enigma that most physicians are keen to learn about and use cutting edge medicines and devices for their patients, but are often apathetic or worse when it comes to new communication technologies and digital information exchange. Where else can you spot a fax machine being actively used these days, outside of a hospital or doctor’s office? Even with the federal government writing checks to those physicians willing to use electronic health records in a meaningful way, many are still dawdling on implementation, which makes the meteoric uptake of the iPad by physicians something of a surprise. Sixty-two percent of physicians in the US now have one kind of tablet or another, but mostly its iPads. Big Pharma recognized the trend and passed out iPads to its sales forces; physicians who previously wouldn’t give a rep the time of day were suddenly being engaged for twice as long on a detail. With four in ten physicians telling Manhattan Research that they use a tablet between patient consultations, and reporting that online medical journals are the number one destination at that time, it makes sense that journals themselves get on board. To that end, Wolters Kluwer’s Lippincott Williams & Wilkins (LWW) journals are making it easier for pharma and device marketers to reach physicians while they’re at work, by offering app versions of their journals and taking advantage of the interactive tools and rich media capabilities offered by the device. In the journal Neurology, for example, Acorda Therapeutics’ began a series of ads for Ampyra – a drug indicated for the improvement of walking in patients with multiple sclerosis – with a detailed mechanism of action video placement. The company followed it up with a before and after video featuring a real MS patient in a side by side, struggling to walk normally before Ampyra, and walking markedly better after having taken the drug. In addition to advertising, authors submitting papers to LWW journals can also submit video to accompany the text, things like recorded surgical procedures or a conversational summary of an article or topic. “No one reading a print journal follows a directive to watch a video online,” says Karen Abramson, president and CEO of Wolters Kluwer Health Medical Research. “The [iPad] platform has enabled us to engage physicians with content they probably wouldn’t have seen otherwise.” LWW journal apps across six specialties showed that iPad readers interacted with an ad, on average, for somewhere between 10 and 40 seconds, according to LWW’s preliminary internal data. What is unique about the journal apps and their capabilities, says Abramson, is the model. Instead of buying print or online journal ads, LWW “sells the whole audience;” a bundled model versus selling individual channels. Some of the medical societies have even begun to cease printing their journals, and have gone completely digital with journal apps, notes Abramson. Perhaps some day physicians will give up their manila folders stuffed with loose leaf and xeroxed patient records. Via uri goren
Scoop.it!
La e-santé, bien que fortement encouragée par le gouvernement, peine à trouver sa place dans le système de santé français. Via EVELYNE PIERRON
Scoop.it!
Researchers are using big data analytics to help improve the quality of life of multiple sclerosis patients. To improve health care, researchers are using big data analytics to bring advances to the medical field. For example, at the State University of New York (SUNY) in Buffalo researchers are using data from patients with multiple sclerosis to analyze the effectiveness of current drugs and treatments alongside the individual’s personal health records and the progression of the disease. . Via Alex Butler
Scoop.it!
Pharmaceutical Industry | NEWS | | European doctor communities forge closer ties - iVrach, Mediquality and Doktor Sitesi join Networks in Health | PMLiVE...
|
